Dr. Dinesh Kumar Mangal

Dr. Dinesh Kumar Mangal is a distinguished Consultant in Radiation Oncology at Manipal Hospitals, Jaipur, with a robust academic background comprising an MBBS and an MD in Radiation Oncology. He is renowned for his precision in diagnosis and delivering patient-centric care, making him a trusted choice for individuals seeking advanced cancer treatment.

Dr. Mangal's clinical expertise encompasses a comprehensive range of services in cancer care. He specialises in the preventive and early diagnosis of cancer, overall clinical management of cancer patients, and is proficient in the latest radiotherapy treatments such as Stereotactic Body Radiotherapy (SBRT), Stereotactic Radiosurgery (SRS), Stereotactic Radiotherapy (SRT), Image-Guided Radiotherapy (IGRT), and Intensity-Modulated Radiotherapy (IMRT). Additionally, he is adept at all types of brachytherapy applications. His treatment approaches have yielded promising results in various cancers, including those of the brain, spinal cord, head and neck, lung, breast, esophagus, stomach, kidney, colon, prostate, urogenital, and gynaecological regions.

Beyond his clinical practice, Dr. Mangal is actively involved in the academic and research domains of oncology. He has contributed to numerous publications and is a sought-after speaker at medical conferences, where he shares insights on cancer treatment advancements. His commitment to the field is further demonstrated by his memberships in several esteemed professional organizations, including the American Society of Therapeutic Radiation Oncology (ASTRO), the Union for International Cancer Control (UICC), the Association of Radiation Oncologists of India (AROI), the Indian Medical Association (IMA), the National Medicos Organisation (NMO), the Society of Nuclear Medicine, India, the Medical Practitioners Society (MPS), and the Neuro Oncology Society of India (NOSI).

Dr. Mangal's excellence in oncology has been recognised with accolades such as the Chikitsa Vibhushan Award by the Jaipur Medical Association on Doctor's Day in July 2018. Notably, he played a pivotal role in establishing a well-equipped radiotherapy centre in Benghazi, Libya, which was certified by the Great Socialist People's Libyan Arab Jamahiriya in July 1997. He is also credentialed and approved by the Radiation Therapy Oncology Group (RTOG) to enrol patients in the PROCLAIM protocol for non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy.

Dr. Dinesh Kumar Mangal is a distinguished Consultant in Radiation Oncology at Manipal Hospitals, Jaipur, with a robust academic background comprising an MBBS and an MD in Radiation Oncology. He is renowned for his precision in diagnosis and delivering patient-centric care, making him a trusted choice for individuals seeking advanced cancer treatment.

Dr. Mangal's clinical expertise encompasses a comprehensive range of services in cancer care. He specialises in the preventive and early diagnosis of cancer, overall clinical management of cancer patients, and is proficient in the latest radiotherapy treatments such as Stereotactic Body Radiotherapy (SBRT), Stereotactic Radiosurgery (SRS), Stereotactic Radiotherapy (SRT), Image-Guided Radiotherapy (IGRT), and Intensity-Modulated Radiotherapy (IMRT). Additionally, he is adept at all types of brachytherapy applications. His treatment approaches have yielded promising results in various cancers, including those of the brain, spinal cord, head and neck, lung, breast, esophagus, stomach, kidney, colon, prostate, urogenital, and gynaecological regions.

Beyond his clinical practice, Dr. Mangal is actively involved in the academic and research domains of oncology. He has contributed to numerous publications and is a sought-after speaker at medical conferences, where he shares insights on cancer treatment advancements. His commitment to the field is further demonstrated by his memberships in several esteemed professional organizations, including the American Society of Therapeutic Radiation Oncology (ASTRO), the Union for International Cancer Control (UICC), the Association of Radiation Oncologists of India (AROI), the Indian Medical Association (IMA), the National Medicos Organisation (NMO), the Society of Nuclear Medicine, India, the Medical Practitioners Society (MPS), and the Neuro Oncology Society of India (NOSI).

Dr. Mangal's excellence in oncology has been recognised with accolades such as the Chikitsa Vibhushan Award by the Jaipur Medical Association on Doctor's Day in July 2018. Notably, he played a pivotal role in establishing a well-equipped radiotherapy centre in Benghazi, Libya, which was certified by the Great Socialist People's Libyan Arab Jamahiriya in July 1997. He is also credentialed and approved by the Radiation Therapy Oncology Group (RTOG) to enrol patients in the PROCLAIM protocol for non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy.

Dr. Dinesh Kumar Mangal is a distinguished Consultant in Radiation Oncology at Manipal Hospitals, Jaipur, with a robust academic background comprising an MBBS and an MD in Radiation Oncology. He is renowned for his precision in diagnosis and delivering patient-centric care, making him a trusted choice for individuals seeking advanced cancer treatment.

Dr. Mangal's clinical expertise encompasses a comprehensive range of services in cancer care. He specialises in the preventive and early diagnosis of cancer, overall clinical management of cancer patients, and is proficient in the latest radiotherapy treatments such as Stereotactic Body Radiotherapy (SBRT), Stereotactic Radiosurgery (SRS), Stereotactic Radiotherapy (SRT), Image-Guided Radiotherapy (IGRT), and Intensity-Modulated Radiotherapy (IMRT). Additionally, he is adept at all types of brachytherapy applications. His treatment approaches have yielded promising results in various cancers, including those of the brain, spinal cord, head and neck, lung, breast, esophagus, stomach, kidney, colon, prostate, urogenital, and gynaecological regions.

Beyond his clinical practice, Dr. Mangal is actively involved in the academic and research domains of oncology. He has contributed to numerous publications and is a sought-after speaker at medical conferences, where he shares insights on cancer treatment advancements. His commitment to the field is further demonstrated by his memberships in several esteemed professional organizations, including the American Society of Therapeutic Radiation Oncology (ASTRO), the Union for International Cancer Control (UICC), the Association of Radiation Oncologists of India (AROI), the Indian Medical Association (IMA), the National Medicos Organisation (NMO), the Society of Nuclear Medicine, India, the Medical Practitioners Society (MPS), and the Neuro Oncology Society of India (NOSI).

Dr. Mangal's excellence in oncology has been recognised with accolades such as the Chikitsa Vibhushan Award by the Jaipur Medical Association on Doctor's Day in July 2018. Notably, he played a pivotal role in establishing a well-equipped radiotherapy centre in Benghazi, Libya, which was certified by the Great Socialist People's Libyan Arab Jamahiriya in July 1997. He is also credentialed and approved by the Radiation Therapy Oncology Group (RTOG) to enrol patients in the PROCLAIM protocol for non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy.

Dr. Dinesh Kumar Mangal is a distinguished Consultant in Radiation Oncology at Manipal Hospitals, Jaipur, with a robust academic background comprising an MBBS and an MD in Radiation Oncology. He is renowned for his precision in diagnosis and delivering patient-centric care, making him a trusted choice for individuals seeking advanced cancer treatment.

Dr. Mangal's clinical expertise encompasses a comprehensive range of services in cancer care. He specialises in the preventive and early diagnosis of cancer, overall clinical management of cancer patients, and is proficient in the latest radiotherapy treatments such as Stereotactic Body Radiotherapy (SBRT), Stereotactic Radiosurgery (SRS), Stereotactic Radiotherapy (SRT), Image-Guided Radiotherapy (IGRT), and Intensity-Modulated Radiotherapy (IMRT). Additionally, he is adept at all types of brachytherapy applications. His treatment approaches have yielded promising results in various cancers, including those of the brain, spinal cord, head and neck, lung, breast, esophagus, stomach, kidney, colon, prostate, urogenital, and gynaecological regions.

Beyond his clinical practice, Dr. Mangal is actively involved in the academic and research domains of oncology. He has contributed to numerous publications and is a sought-after speaker at medical conferences, where he shares insights on cancer treatment advancements. His commitment to the field is further demonstrated by his memberships in several esteemed professional organizations, including the American Society of Therapeutic Radiation Oncology (ASTRO), the Union for International Cancer Control (UICC), the Association of Radiation Oncologists of India (AROI), the Indian Medical Association (IMA), the National Medicos Organisation (NMO), the Society of Nuclear Medicine, India, the Medical Practitioners Society (MPS), and the Neuro Oncology Society of India (NOSI).

Dr. Mangal's excellence in oncology has been recognised with accolades such as the Chikitsa Vibhushan Award by the Jaipur Medical Association on Doctor's Day in July 2018. Notably, he played a pivotal role in establishing a well-equipped radiotherapy centre in Benghazi, Libya, which was certified by the Great Socialist People's Libyan Arab Jamahiriya in July 1997. He is also credentialed and approved by the Radiation Therapy Oncology Group (RTOG) to enrol patients in the PROCLAIM protocol for non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy.

Dr. Dinesh Kumar Mangal is a distinguished Consultant in Radiation Oncology at Manipal Hospitals, Jaipur, with a robust academic background comprising an MBBS and an MD in Radiation Oncology. He is renowned for his precision in diagnosis and delivering patient-centric care, making him a trusted choice for individuals seeking advanced cancer treatment.

Dr. Mangal's clinical expertise encompasses a comprehensive range of services in cancer care. He specialises in the preventive and early diagnosis of cancer, overall clinical management of cancer patients, and is proficient in the latest radiotherapy treatments such as Stereotactic Body Radiotherapy (SBRT), Stereotactic Radiosurgery (SRS), Stereotactic Radiotherapy (SRT), Image-Guided Radiotherapy (IGRT), and Intensity-Modulated Radiotherapy (IMRT). Additionally, he is adept at all types of brachytherapy applications. His treatment approaches have yielded promising results in various cancers, including those of the brain, spinal cord, head and neck, lung, breast, esophagus, stomach, kidney, colon, prostate, urogenital, and gynaecological regions.

Beyond his clinical practice, Dr. Mangal is actively involved in the academic and research domains of oncology. He has contributed to numerous publications and is a sought-after speaker at medical conferences, where he shares insights on cancer treatment advancements. His commitment to the field is further demonstrated by his memberships in several esteemed professional organizations, including the American Society of Therapeutic Radiation Oncology (ASTRO), the Union for International Cancer Control (UICC), the Association of Radiation Oncologists of India (AROI), the Indian Medical Association (IMA), the National Medicos Organisation (NMO), the Society of Nuclear Medicine, India, the Medical Practitioners Society (MPS), and the Neuro Oncology Society of India (NOSI).

Dr. Mangal's excellence in oncology has been recognised with accolades such as the Chikitsa Vibhushan Award by the Jaipur Medical Association on Doctor's Day in July 2018. Notably, he played a pivotal role in establishing a well-equipped radiotherapy centre in Benghazi, Libya, which was certified by the Great Socialist People's Libyan Arab Jamahiriya in July 1997. He is also credentialed and approved by the Radiation Therapy Oncology Group (RTOG) to enrol patients in the PROCLAIM protocol for non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy.